Price · as of 2025-06-30
$1.59
Market cap 44.53M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.37 | +1,935.85% |
| Intrinsic Value(DCF) | $0.34 | -78.62% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9,650.00 | $0.00 | $0.00 | ||
| 2012 | $5,550.00 | $4,533.03 | $5,965.18 | $0.00 | $0.00 |
| 2013 | $2,350.00 | $22,776.29 | $0.00 | $0.00 | $7,623.60 |
| 2014 | $2,450.00 | $15,168.18 | $130.37 | $0.00 | $19,798.29 |
| 2015 | $3,600.00 | $3,678.85 | $25,850.55 | $0.00 | $0.00 |
| 2016 | $3,000.00 | $2,527.61 | $0.00 | $0.00 | $23,242.00 |
| 2017 | $1,450.00 | $1,232.70 | $0.00 | $0.00 | $38,919.24 |
| 2018 | $425.00 | $170.00 | $0.00 | $0.00 | $0.00 |
| 2019 | $310.00 | $148.70 | $69.24 | $0.00 | $0.00 |
| 2020 | $965.00 | $606.37 | $242.72 | $0.00 | $1,289.59 |
| 2021 | $585.00 | $289.03 | $153.40 | $0.00 | $0.00 |
| 2022 | $140.00 | $116.12 | $1,453.21 | $0.00 | $33,437.74 |
| 2023 | $5.80 | $79.37 | |||
| 2024 | $1.78 | $0.33 | $0.00 | ||
| 2025 | $0.84 | $32.37 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates iBio, Inc.'s (IBIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.37
- Current price
- $1.59
- AI upside
- +1,935.85%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.34
-78.62% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IBIO | iBio, Inc. | $1.59 | 44.53M | +1,936% | -79% | — | — | -0.48 | 0.59 | 22.05 | -0.22 | — | 1.10 | 100.00% | -4650.50% | -4594.25% | -101.52% | -174.01% | -70.79% | 0.24 | -87.75 | 1.59 | 1.42 | 0.30 | -7308.00% | 7778.00% | -1835.00% | -173.71% | -2.51 | -143.31% | 0.00% | 0.00% | 0.00% | -0.20 | -0.24 | 9.36 | -21.87 |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| CVKD | Cadrenal Therapeutics, In… | $8.49 | 19.85M | — | — | — | — | -1.93 | 2.76 | — | -0.99 | — | 2.76 | 0.00% | — | — | -140.78% | 670.96% | -114.27% | 0.00 | — | 3.77 | 3.75 | 0.94 | -935.00% | — | 10840.00% | -35.84% | -2.74 | 450.80% | 0.00% | 0.00% | 7.97% | -0.96 | -1.43 | — | -1.66 |
| INTS | Intensity Therapeutics, I… | $7.66 | 14.45M | — | — | — | — | -1.89 | 10.53 | — | -1.74 | — | 10.53 | 0.00% | — | — | -202.34% | 3350.51% | -147.37% | 0.05 | — | 1.92 | 1.48 | 0.15 | -1522.00% | — | 11124.00% | -49.52% | -8.67 | 3074.75% | 0.00% | 0.00% | 0.00% | -1.71 | -1.86 | — | -20.70 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| KLTO | Klotho Neurosciences, Inc… | $0.53 | 28.02M | — | — | — | — | -0.90 | 4.69 | — | -1.00 | 0.00 | -4.99 | 0.00% | — | — | -700.07% | -323.09% | -264.53% | 0.23 | -15.54 | 0.13 | 0.05 | -0.04 | 4561429.00% | — | 56623.00% | -55.19% | -2.36 | -179.03% | 0.00% | 0.00% | 24.75% | -1.04 | -1.88 | — | -11.37 |
| PLUR | Pluri Inc. | $3.60 | 29.39M | +873% | -44% | — | — | -1.37 | -4.65 | 23.81 | -2.05 | — | -2.49 | 48.95% | -1659.88% | -1690.34% | 689.30% | -701.84% | -59.46% | -4.98 | -25.40 | 0.68 | 0.66 | -1.28 | -1078.00% | 30982.00% | 810.00% | -62.33% | -0.56 | -627.70% | 0.00% | 0.00% | 0.00% | -2.04 | -2.28 | 33.87 | -17.73 |
| PSTV | Plus Therapeutics, Inc. | $0.30 | 18.31M | +20,855% | +1,192% | — | — | -0.80 | -1.16 | 1.79 | -1.21 | — | -1.06 | 85.37% | -252.32% | -222.84% | 252.07% | 197.13% | -144.03% | -0.38 | -3.95 | 0.34 | 0.27 | -0.39 | -4481.00% | 1854.00% | -1776.00% | -102.64% | -0.68 | 143.54% | 0.00% | 0.00% | 3.59% | -0.69 | -0.95 | 1.75 | -112.05 |
| RLYB | Rallybio Corporation | $7.54 | 39.81M | — | — | — | — | -0.56 | 0.53 | 50.94 | 0.55 | — | 0.53 | 100.00% | -9511.95% | -9084.12% | -68.85% | 1714.74% | -62.89% | 0.00 | — | 10.87 | 10.50 | 0.23 | -2772.00% | — | -1824.00% | -152.12% | -7.90 | 1396.88% | 0.00% | 0.00% | 0.00% | 0.54 | 0.67 | -51.82 | -4.85 |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
- CEO
- Martin Brenner
- Employees
- 16
- Beta
- 1.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.34 ÷ $1.59) − 1 = -78.62% (DCF, example).